...
首页> 外文期刊>Endocrine journal >Ratio of Serum Free Triiodothyronine to Free Thyroxine in Graves' Hyperthyroidism and Thyrotoxicosis Caused by Painless Thyroiditis
【24h】

Ratio of Serum Free Triiodothyronine to Free Thyroxine in Graves' Hyperthyroidism and Thyrotoxicosis Caused by Painless Thyroiditis

机译:无痛性甲状腺炎引起的格雷夫斯甲状腺功能亢进症和甲状腺毒症中血清游离甲状腺素和甲状腺素的比率

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The serum T_3 to T_4 ratio is a useful indicator for differentiating destruction-induced thyrotoxicosis from Graves' thyrotoxicosis. However, the usefulness of the serum free T_3 (FT_3) to free T_4 (FT_4) ratio is controversial. We therefore systematically evaluated the usefulness of this ratio, based on measurements made using two widely available commercial kits in two hospitals. Eighty-two untreated patients with thyrotoxicosis (48 patients with Graves' disease and 34 patients with painless thyroiditis) were examined in Kuma Hospital, and 218 patients (126 with Graves' disease and 92 with painless thyroiditis) and 66 normal controls were examined in Ito Hospital. The FT_3 and FT_4 values, as well as the FT_3/FT_4 ratios, were significantly higher in the patients with Graves' disease than in those with painless thyroiditis in both hospitals, but considerable overlap between the two disorders was observed. Receiver operating characteristic (ROC) curves for the FT_3 and FT_4 values and the FT_3/FT_4 ratios of patients with Graves' disease and those with painless thyroiditis seen in both hospitals were prepared, and the area under the curves (AUC), the cut-off points for discriminating Graves' disease from painless thyroiditis, the sensitivity, and the specificity were calculated. AUC and sensitivity of the FT_3/FT_4 ratio were smaller than those of FT_3 and FT_4 in both hospitals. The patients treated at Ito hospital were then divided into 4 groups according to their FT_4 levels (A: ≤ 2.3, B: > 2.3~≤3.9, C: 3.9~≤5.4, D: >5.4 ng/dl), and the AUC, cutoff points, sensitivity, and specificity of the FT_3/FT_4 ratios were calculated. The AUC and sensitivity of each group increased with the FT_4 levels (AUC: 57.8%, 72.1%, 91.1%, and 93.4%, respectively; sensitivity: 62.6%, 50.0%, 77.8%, and 97.0%, respectively). The means ± SE of the FT_3/FT_4 ratio in the Graves' disease groups were 3.1 ± 0.22, 3.1 ± 0.09, 3.2 ±0.06, and 3.1 ± 0.07, respectively, versus 2.9 ±0.1, 2.6 ±0.07, 2.5 ±0.12, and 2.3 ±0.15, respectively, in the painless thyroiditis groups. In the painless thyroiditis patients, the difference in the FT_3/FT_4 ratio between group A and group D was significant (p<0.05). Thus, the FT_3/FT_4 ratio in patients with Graves' disease likely remains unchanged as the FT_4 level rises, whereas this ratio decreases as the FT_4 level rises in patients with painless thyroiditis. In conclusion, the FT_3/FT_4 ratios of patients with painless thyroiditis overlapped with those of patients with Graves' disease. However, this ratio was useful for differentiating between these two disorders when the FT_4 values were high.
机译:血清T_3与T_4之比是区分破坏引起的甲状腺毒症和格雷夫斯甲状腺毒症的有用指标。但是,血清游离T_3(FT_3)与游离T_4(FT_4)之比的有用性存在争议。因此,我们基于在两家医院使用两种广泛使用的商业套件进行的测量,系统地评估了该比率的有效性。在库马医院检查了82例未经治疗的甲状腺毒症患者(48例Graves病患者和34例无痛性甲状腺炎患者),对218例患者(Graves病126例,无痛性甲状腺炎92例)和66例正常对照者进行了伊藤检查医院。两家医院的Graves病患者的FT_3和FT_4值以及FT_3 / FT_4的比率均显着高于无痛性甲状腺炎的患者,但观察到两种疾病之间存在相当大的重叠。绘制了两家医院中Graves病患者和无痛性甲状腺炎患者的FT_3和FT_4值以及FT_3 / FT_4比率的接收器工作特征(ROC)曲线,曲线下的面积(AUC)计算区分格雷夫斯病和无痛性甲状腺炎的起点,敏感性和特异性。两家医院的FT_3 / FT_4比值的AUC和灵敏度均小于FT_3和FT_4的AUC和灵敏度。然后根据伊藤医院的FT_4水平将患者分为4组(A:≤2.3,B:> 2.3〜≤3.9,C:3.9〜≤5.4,D:> 5.4 ng / dl),以及AUC ,计算了FT_3 / FT_4比率的临界点,敏感性和特异性。每组的AUC和敏感性均随FT_4水平的升高而升高(AUC分别为57.8%,72.1%,91.1%和93.4%;敏感性:分别为62.6%,50.0%,77.8%和97.0%)。格雷夫斯病组中FT_3 / FT_4比率的平均值±SE分别为2.9±0.1、2.6±0.07、2.5±0.12和3.1±0.22、3.1±0.09、3.2±0.06和3.1±0.07无痛性甲状腺炎组分别为2.3±0.15。在无痛性甲状腺炎患者中,A组和D组之间的FT_3 / FT_4比值差异显着(p <0.05)。因此,格雷夫斯病患者的FT_3 / FT_4比值可能随着FT_4水平的升高而保持不变,而该比例随着无痛性甲状腺炎患者的FT_4水平的升高而降低。总之,无痛性甲状腺炎患者的FT_3 / FT_4比值与Graves病患者的FT_3 / FT_4比值重叠。但是,当FT_4值较高时,该比率可用于区分这两种疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号